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Systemic RAGE ligands are upregulated in
tuberculosis individuals with diabetes co-
morbidity and modulated by anti-
tuberculosis treatment and metformin
therapy
Nathella Pavan Kumar1* , Kadar Moideen1, Arul Nancy1,2, Vijay Viswanathan2, Basavaradhya S. Shruthi2,
Shanmugam Sivakumar3, Syed Hissar3, Hardy Kornfeld4 and Subash Babu1,5
Abstract
Background: Ligands of the receptor for advanced glycation end products (RAGE) are key signalling molecules in the
innate immune system but their role in tuberculosis-diabetes comorbidity (TB-DM) has not been investigated.
Methods: We examined the systemic levels of soluble RAGE (sRAGE), advanced glycation end products (AGE), S100A12
and high mobility group box 1 (HMGB1) in participants with either TB-DM, TB, DM or healthy controls (HC).
Results: Systemic levels of AGE, sRAGE and S100A12 were significantly elevated in TB-DM and DM in comparison to TB
and HC. During follow up, AGE, sRAGE and S100A12 remained significantly elevated in TB-DM compared to TB at 2nd
month and 6th month of anti-TB treatment (ATT). RAGE ligands were increased in TB-DM individuals with bilateral and
cavitary disease. sRAGE and S100A12 correlated with glycated hemoglobin levels. Within the TB-DM group, those with
known diabetes (KDM) revealed significantly increased levels of AGE and sRAGE compared to newly diagnosed DM
(NDM). KDM participants on metformin treatment exhibited significantly diminished levels of AGE and sRAGE in
comparison to those on non-metformin regimens.
Conclusions: Our data demonstrate that RAGE ligand levels reflect disease severity and extent in TB-DM, distinguish
KDM from NDM and are modulated by metformin therapy.
Keywords: Mycobacterium tuberculosis, Diabetes mellitus, RAGE ligands
Background
The co-prevalence of tuberculosis (TB) and diabetes
mellitus (DM) has grown into a major barrier to TB
elimination. DM and TB are foremost killers of mankind
around the globe [1]. Since DM increases the risk of
progress of latent TB infection (LTBI) to active tubercu-
losis threefold [2, 3], the coexistence of the two diseases
jeopardizes global health and justifies routine bidirec-
tional screening [4]. DM affects the immune system by
worsening both innate and adaptive immune functions,
which in turn leads to increased risk of poor TB out-
comes plus increased transmission, poorer clinical pres-
entation, treatment failure and death [5–10].
RAGE is a multiligand receptor of the immunoglobu-
lin superfamily involved in inflammation, DM and its as-
sociated complications [11, 12]. Of the defined pathways
implicated in the pathogenesis of diabetic complications,
RAGE receptor signalling has been the most widely
studied in leukocytes, immune function, and response to
infection. The RAGE receptor signals through binding of
not only AGEs, as the name implies, but also the A8, A9
and A12 members of S100 protein family, the cellular
stress signalling protein, high mobility group box 1
(HMGB-1), and β-amyloid sheets [13]. All of these
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ligands are either direct products of high glucose or are
induced by the cellular stress of hyperglycemia [14]. The
formation of RAGE ligands might be relevant to TB-DM
comorbidity because RAGE ligands are known to accu-
mulate to a greater level with DM and also in the pres-
ence of chronic inflammation, such as that which occurs
in TB [12]. It is possible that RAGE ligands may accu-
mulate at a faster rate in people with TB-DM, given the
convergence of hyperglycemia and chronic inflamma-
tion. RAGE ligand upregulation may alter immune cell
function and lead to a prolonged proinflammatory re-
sponse through RAGE-mediated activation of nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-kB) [15, 16].
In our current data, we elucidated the systemic levels
of RAGE ligands at baseline and at two time-points fol-
lowing initiation of anti-TB treatment (ATT): 2 months,
which marks the end of the intensive phase, and 6
months, when treatment is completed. Our data demon-
strate that DM differentially modulates the circulating
RAGE ligands in participants with TB before, during and
after completion of anti-TB treatment. Our current find-
ings also reveal that systemic RAGE ligands levels indi-
cate baseline disease severity and extent in TB-DM,
discriminate KDM from NDM and are altered by ATT
and metformin therapy.
Methods
Study population
We recruited and collected the plasma samples from a
group of active pulmonary TB individuals with diabetes
mellitus (TB-DM) (n = 44), individuals with active pul-
monary TB (TB) alone (n = 44), individuals with diabetes
mellitus (DM) alone (n = 44) and healthy control individ-
uals with no TB or diabetes (HC) ) (n=30) recruited in
Chennai, India (Table 1). This was the same set of indi-
viduals previously used for studying the association of
monocyte activation markers with TB-DM and we used
the same methodology previously described by Kumar
NP et al., [17]. Pulmonary TB cases were microbiologic-
ally confirmed based on smear and culture positivity for
Mycobacterium tuberculosis (M.tb). For defining cavitary
disease and lung lesions, chest X-rays were used. The
breakup is as follows: cavitary disease (TB-DM, n = 13
and TB, n = 10) and non-cavitary disease (TB-DM, n =
31 and TB, n = 34) as well as unilateral (TB-DM, n = 24
and TB, n = 25) versus bilateral (TB-DM, n = 20 and TB,
n = 19) lung involvement. Bacterial burdens were esti-
mated using the AFB smear grades and classified as 1+
(TB-DM, n = 14 and TB, n = 19), 2+ (TB-DM, n = 19 and
TB, n = 14) and 3+ (TB-DM, n = 11 and TB, n = 11). All
the active TB cases had no record of prior TB disease or
ATT during the time of enrolment. Oral glucose toler-
ance test and/or glycated hemoglobin (HbA1c) levels
(for known diabetics) were used for diagnosing the gly-
cemic status (DM or normoglycemia) according to the
WHO criteria. Among the 44 TB-DM individuals, 22
were known diabetics (KDM) and 22 were newly diag-
nosed diabetics (NDM). Patients with prior history of
diabetes were confirmed by HbA1c testing and grouped
as known diabetic (KDM). Those with no prior history
of diabetes were assessed by fasting plasma glucose
(FPG) test and oral glucose tolerance test (OGTT) (75-g
glucose challenge). Glycemic status based on plasma glu-
cose 2 h post-challenge was determined according to
World Health Organization (WHO) criteria: DM (> 200
mg/dL), impaired glucose tolerance (140 to 199mg/dL),
normoglycemia (< 140 mg/dL). These individuals were
grouped as NDM and the diagnosis was made at the
time of TB diagnosis. Among the KDM individuals, pa-
tients were classified as those who were taking metfor-
min containing anti-diabetic medication (n = 11) and
patients who were on insulin or glimepiride (n = 11)
(Table 2). All the recruited DM and HC individuals were
Table 1 Demographic and clinical variables of the study groups and biochemical parameters in TB-DM, TB, DM and HC
Study Demographics TB-DM TB DM HC
KDM NDM
Number of subjects recruited 22 22 44 44 30
Gender (Male / Female) 16/6 18/4 27/17 30/14 15/15
Median Age (Range) 52 (25–70) 42 (29–70) 39 (24–67) 44 (33–68) 34 (23–55)
BMI kg/m2 21.7 (13.2–28.6) 17.2 (13.2–32.6) 16.5 (13.2–30.1) 20.1 (14.2–32.1) 20.1 (18.2–25.3)
Smear Grade: 0/1+/2+/3+ 0/4/10/8 0/10/9/3 0/19/14/11 NA NA
Cavitary Disease (Y/N) 9/13 4/18 10/34 NA NA
Lung Lesions (Unilateral/Bilateral) 13/9 11/11 25/19 NA NA
Fasting Blood Glucose, mg/dL 166 (120–417) 139 (111–375) 93 (73–103) 144 (95–405) 75 (70–109)
Post-prandial Glucose, mg/dL 350 (217–550) 311 (202–505) 110 (68–137) 341 (210–543) 98 (72–139)
Glycated hemoglobin level, % 12.3 (8–15.6) 10 (7.3–13.9) 5.6 (5.0–5.8) 10 (6.8–12.6) 5.5 (5.0–5.9)
The values represent the geometric mean (and the 95% confidence intervals) except for age where the median (and the range) are depicted
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negative for Quantiferon TB gold assay with no clinical
symptoms of TB and normal chest X-rays. To all the en-
rolled TB-DM and TB individuals, standard ATT using
the directly observed treatment, short course (DOTS)
strategy was administered. At the end 2 and 6months of
ATT, fresh plasma samples were collected from TB-DM
and TB individuals. All the enrolled TB-DM and TB in-
dividuals were culture negative at the end of ATT.
Elisa
Circulating levels of AGE (carboxymethyl lysine) were
measured using the Cell Biolabs INC kit. Soluble RAGE
(sRAGE) was measured using the Quantikine ELISA kit
(R&D Systems), S100A12 using the MBL international
corporation kit and HMGB-1 using the Mybiosource kit.
The lowest detection limits were as follows: AGE, 0.39
μg/mL; sRAGE, 78.12 pg/mL; S100A12, 20 pg/mL and
HMGB-1, 19.5 pg/mL.
Statistical analysis
For measuring the central tendency, Geometric means
(GM) were used. Kruskal-Wallis test with Dunn’s cor-
rection for multiple comparisons were used for analysing
the statistically significant differences between the four
groups. The Mann-Whitney test was used to compare
RAGE ligand concentrations between TB patients with
and without DM, unilateral or bilateral lung lesions and
cavitary or non-cavitary disease. Linear trend post-test
was used to compare RAGE ligand concentrations with
smear grades (reflecting bacterial burdens) and Spear-
man rank correlation was used to compare RAGE ligand
concentrations with HbA1c levels. Analyses were per-
formed using GraphPad PRISM Version 7.
Results
Study population characteristics
The baseline characteristics including demographic and
biochemical features of the study population are shown
in Table 1. No significant differences were observed in
age, sex, smear or culture grades at baseline between the
TB-DM and TB groups (Table 1).
Elevated levels of circulating RAGE ligands in TB-DM
To elucidate the effect of TB and DM on systemic
RAGE ligand expression, we estimated the plasma levels
of AGE, sRAGE, S100A12 and HMGB-1 in TB-DM, TB,
DM and HC individuals (Fig. 1). Plasma levels of AGE
(Geo Mean 4.65 pg/ml in TB-DM vs 2.93 pg/ml in TB,
3.25 pg/ml in DM and 2.04 pg/ml in HC), sRAGE (Geo
Mean 541.2 pg/ml in TB-DM vs 345.6 pg/ml in TB,
475.1 pg/ml in DM and 307.7 pg/ml in HC) and
S100A12 (Geo Mean 2222 pg/ml in TB-DM vs 1286 pg/
ml in TB, 2018 pg/ml in DM and 254 pg/ml in HC) were
significantly increased in TB-DM and DM in compari-
son with TB and HC study participants. In contrast, the
circulating levels of HMGB-1 (Geo Mean 31.1 pg/ml in
TB-DM vs 34.5 pg/ml in TB, 46.8 pg/ml in DM and 41.7
pg/ml in HC) was significantly higher in DM in com-
parison with TB-DM, TB and HC. Thus, DM with or
without coexisting TB disease was associated with sig-
nificantly increased plasma levels of RAGE ligands and
sRAGE, while only DM was associated with elevated
HMGB-1.
Elevated circulating levels of RAGE ligands in TB-DM
compared to TB during ATT
To elucidate whether the RAGE ligands or sRAGE were
changed by anti-TB treatment, we estimated the circu-
lating plasma levels of AGE, sRAGE, S100A12 and
HMGB-1 in TB-DM and TB at baseline (pre-treatment),
during treatment (2nd month) and at the completion of
ATT (6th month). As shown in Fig. 2, AGE (Geo Mean
of 4.88 pg/ml in TB-DM vs 2.52 pg/ml in TB); sRAGE
(Geo Mean 635.2 pg/ml in TB-DM vs 425.6 pg/ml in
TB) and S100A12 (Geo Mean 2018 pg/ml in TB-DM vs
1073 pg/ml in TB) levels remained significantly increased
in TB-DM compared to TB at 2 months treatment. The
differentially elevated levels of AGE (Geo Mean 11.5 pg/
ml in TB-DM vs 7.8 pg/ml in TB) and sRAGE (Geo
Mean 614.6 pg/ml in TB-DM vs 369.6 pg/ml in TB) per-
sisted through the completion of ATT, whereas the dif-
ference in S100A12 levels (Geo Mean 773.1 pg/ml in
TB-DM vs 897.7 pg/ml in TB) was extinguished by
month 6. This result suggests that elevation of AGE and
sRAGE are intrinsic to the diabetic state, whereas
S100A12 may be at least partially regulated by TB dis-
ease activity.
Table 2 Demographic and clinical variables of the study groups
and biochemical parameters in KDM individuals who are on
metformin and non-metformin treatment
Study Demographics TB-DM
KDM
Metformin Non-metformin
No. of subjects recruited 11 11
Gender (Male/Female) 8/3 8/3
Median Age (Range) 50 (25–70) 48 (30–65)
BMI kg/m2 20.85 (15.5–28.6) 20.97 (13.8–26.1)
Diabetic Medications Metformin Insulin+Glimepiride
Smear Grade: 0/1+/2+/3+ 0/3/4/4 0/1/6/4
Cavitary Disease (Y/N) 4/7 5/6
Lung Lesions (Unilateral/Bilateral) 7/4 6/5
Glycated hemoglobin level, % 11 (7.7–15.6) 10.2 (7.9–14.3)
The values represent the geometric mean (and the 95% confidence intervals)
except for age where the median (and the range) are depicted
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Circulating RAGE ligands as markers of disease severity in
TB-DM
To elucidate the relationship between the circulating
plasma levels of RAGE ligands and disease severity in
TB-DM, based on chest X-ray we compared plasma
levels of AGE, sRAGE, S100A12 and HMGB-1 in TB-DM
and TB study participants with unilateral vs bilateral dis-
ease and cavitary vs non-cavitary disease. As shown in
Fig. 3a, the systemic plasma levels of AGE (Geo Mean
6.28 pg/ml in bilateral vs. 3.62 pg/ml in unilateral disease),
Fig. 1 Enhanced circulating levels of RAGE ligands in TB-DM and DM participants. The plasma levels of AGE, sRAGE, S100A12 and HMGB-1 were
measured in TB-DM (n = 44), TB (n = 44), DM (n = 44) and HC (n = 30) individuals at baseline. The data are illustrated as scatter plots with each
circle representing a single participant. P values were calculated using the Kruskal-Wallis test with Dunn’s post-hoc for multiple comparisons
Fig. 2 TB-DM is associated with increased frequencies of RAGE ligands at pre-treatment and following ATT. The plasma levels of RAGE ligands in
TB-DM (n = 44) and TB (n = 44) participants at pre-treatment and at two and six months following ATT. The data are illustrated as scatter plots
with each circle representing a single participant. P values were calculated using the Mann-Whitney test
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sRAGE (Geo Mean 693.4 pg/ml in bilateral vs. 440.7 pg/
ml in unilateral disease) and S100A12 (Geo Mean 3079
pg/ml in bilateral vs. 1693 pg/ml in unilateral disease)
were significantly increased in TB-DM individuals with bi-
lateral disease in comparison with unilateral disease. In
contrast, no significant differences were seen between bi-
lateral vs unilateral disease in TB individuals without dia-
betes (Additional file 1: Table S1). As shown in Fig. 3b,
systemic plasma levels of AGE (Geo Mean 6.13 pg/ml in
cavitary vs. 4.14 pg/ml in non-cavitary disease), sRAGE
(Geo Mean 737.9 pg/ml in cavitary vs. 475.6 pg/ml in non-
cavitary disease) and S100A12 (Geo Mean 3264 pg/ml in
cavitary vs. 1891 pg/ml in non-cavitary disease) were sig-
nificantly increased in TB-DM individuals with cavi-
tary disease in comparison with those without. In
contrast, no significant differences were seen between
cavitary vs non-cavitary disease in TB individuals
without diabetes (Additional file 2: Table S2). To de-
termine the association of the systemic levels of RAGE
ligands and bacterial burdens, we performed a
Fig. 3 Increased circulating levels of AGE and sRAGE in bilateral and cavitary disease and also marker of bacterial burden in TB-DM participants. a
The plasma levels of AGE, sRAGE, S100A12 and HMGB-1 were measured in TB-DM individuals with bilateral versus unilateral disease. b The plasma
levels of AGE, sRAGE, S100A12 and HMGB-1 were measured in TB-DM individuals with cavitary versus non-cavitary disease. c The relationship
between the plasma levels of AGE, sRAGE, S100A12 and HMGB-1 and smear grades as measured by sputum smears was examined in TB-DM
individuals. The data are illustrated as scatter plots with each circle representing a single participant. P values were calculated using the Mann-
Whitney test with Holm’s correction for multiple comparisons. For bacterial burden correlation, P values were calculated using the Linear
trend post-test
Kumar et al. BMC Infectious Diseases         (2019) 19:1039 Page 5 of 10
correlation of the circulating levels of AGE, sRAGE,
S100A12 and HMGB-1 in TB-DM and TB individuals
with smear grades. As shown in Fig. 3c, both AGE and
sRAGE displayed a significant positive relationship
with smear grades in TB-DM and TB individuals, indicat-
ing a positive association of these factors with bacterial
burdens. Thus, disease severity assessed radiographically
and by estimated bacterial burden in TB-DM was associ-
ated with elevated systemic levels of RAGE ligands.
Circulating RAGE ligands reveal a positive relationship
with HbA1c in TB-DM, are increased in KDM individuals
and decreased by metformin treatment
To elucidate the relationship between circulating plasma
levels of RAGE ligands and glycemic control in TB-DM, we
determined the association between the systemic levels of
baseline HbA1c with AGE, sRAGE, S100A12 and HMGB-1
in all TB participants with and without DM (Fig. 4a). As
shown, the circulating levels of AGE, sRAGE and S100A12
showed a significant weak positive relationship with HbA1c,
implying an association of these factors with poor glycemic
control. Interestingly, this significant correlation is abol-
ished upon completion of ATT, suggesting that TB per se
has an effect in modulating either RAGE ligands or HbA1c
levels or both. To estimate whether RAGE ligands can dis-
tinguish between KDM (n = 22) and NDM (n = 22) in TB-
DM participants, we first determined the HbA1c levels in
KDM and NDM and observed that HbA1c % was signifi-
cantly increased in KDM in comparison with NDM (Geo-
metric Mean 11.4% in KDM vs 8.9% in NDM, p = 0.0028).
Second, we estimated the baseline levels of AGE, sRAGE,
S100A12 and HMGB-1 in KDM and NDM individuals. As
Fig. 4 Significant correlation between circulating levels of RAGE ligands and glycemic parameters and elevated circulating levels of RAGE ligands
in KDM individuals. a The relationship between the plasma levels of AGE, sRAGE, S100A12 and HMGB-1 and HbA1c levels was examined in all TB
participants with and without DM at baseline. b The plasma levels of AGE, sRAGE, S100A12 and HMGB-1 were measured in TB-DM individuals
with known diabetes (KDM) versus newly diagnosed diabetes (NDM) (c) The plasma levels of AGE, sRAGE, S100A12 and HMGB-1 were measured
in KDM individuals on metformin treatment versus no metformin treatment. The data are illustrated as scatter plots with each circle representing
a single participant. For HbA1c correlations, P values were calculated using the Spearman Rank Correlation. For KDM, P values were calculated
using the Mann-Whitney test with Holm’s correction for multiple comparisons
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shown in Fig. 4b, circulating plasma levels of AGE (Geo
Mean 5.46 pg/ml in KDM vs. 3.96 pg/ml in NDM) and
sRAGE (Geo Mean 675.3 pg/ml in KDM vs. 434.3 pg/ml in
NDM) were significantly increased in KDM in comparison
with NDM participants. Thus, KDM is linked with in-
creased circulating plasma levels of RAGE ligands at base-
line. Since previously published studies reported that anti-
diabetic drug metformin is correlated with protection
against mortality in TB-DM, [18] we estimated the systemic
levels of AGE, sRAGE, S100A12 and HMGB-1 in KDM in-
dividuals on metformin treatment (n = 11) in comparison
with those on non-metformin regimens (n = 11). Among
the KDM study participants on metformin regimen com-
pared to KDM individuals not on metformin regimen, we
found no significant differences in HbA1c levels. As shown
in Fig. 4c, circulating plasma levels of AGE (Geo Mean
4.16 pg/ml in Metformin vs. 7.16 pg/ml in Non-Metformin)
and sRAGE (Geo Mean 560.8 pg/ml in Metformin vs.
813.1 pg/ml in Non-Metformin) were significantly de-
creased in KDM individuals on metformin regimen in com-
parison with KDM individuals not on metformin. Thus,
metformin therapy in KDM individuals is linked with de-
creased circulating plasma levels of AGE and sRAGE, but
no change in the RAGE ligands, S100A12 or HMGB-1.
Systemic RAGE ligands exhibit relationship with pro-
inflammatory cytokines
We have previously measured the systemic plasma levels
of pro-inflammatory cytokines (IL-2, IFNγ and TNFα) in
these individuals and shown that IL-2, IFNγ and TNFα
were significantly enhanced in active TB patients with
DM compared to TB patients without DM [19]. We de-
termined the relationship between the plasma levels of
RAGE ligands in all TB participants with pro-
inflammatory cytokines (Table 3). As shown, the sys-
temic plasma levels of AGE showed a significant positive
relationship with IL-2 and TNFα levels. In addition,
sRAGE showed a significant positive relationship with
IL-2, IFNγ and TNFα in all TB participants with and
without DM at baseline, suggesting a significant associ-
ation of these factors with cytokines.
Discussion
The growing prevalence of DM is a major global health
challenge in its own right, and is further contributing to
the global TB epidemic. Previous studies have described
a detrimental interaction between DM and active TB
[20–23]. DM also has a key adverse effect on TB treat-
ment outcomes [15, 16, 22], including delayed sputum
culture conversion, enhanced risk of treatment failure,
and enhanced risk of TB relapse and mortality [24]. Pub-
lished studies reveal that death attributable to TB is
more prevalent in comorbid individuals after initiating
anti-TB treatment, with a reported 5–7 fold increased
risk overall and 17% mortality after 1 year compared to
7% in patients with TB alone [6, 25, 26]. Better under-
standing of TB-DM pathogenesis might lead to better
therapies.
The RAGE receptor is expressed on diverse immune cell
types including macrophages, neutrophils and lympho-
cytes, but the site of greatest expression is on the pulmon-
ary epithelium [27]. As RAGE was first recognized as a
receptor for AGEs, most of the clinical studies on RAGE
are focused on the diabetic state [28]. Throughout an in-
flammatory response, RAGE–ligand interaction results in
elevated expression of RAGE itself. This positive feedback
loop results in continuous NF-kB activation, thereby alter-
ing a transient proinflammatory response into a chronic
pathophysiological state [29]. A recently published study
has stated that methylglyoxal, an AGE precursor, accumu-
lates during M. tuberculosis infection and which in turn
promotes macrophages apoptosis [30, 31]. During acute
bacterial infections the impact of RAGE signalling in a
non-diabetic state has been previously reported. RAGE
deficiency has been shown to diminish the inflammatory
response to both LPS stimulation and E. coli pneumonia
in mice and drastically improve survival during bacterial
sepsis [32, 33]. In addition, previously published studies
reported the role of RAGE in pulmonary infections, which
may correlate with TB since it is predominantly a pulmon-
ary disease. Studies from murine models have also re-
ported that RAGE is expressed in healthy lungs and are
elevated after infection with M.tb and plays an vital role in
chronic inflammation during tuberculosis [34]. Published
studies from the murine models have shown that en-
hanced mortality was seen during tuberculosis in RAGE
knock out mice, implying a protective role for RAGE li-
gands during murine tuberculosis [34]. With respect to
clinical aspects, studies were reported that soluble RAGEs
may exhibit ability for the identification of patients who
are prone to the complications of diabetes and chronic
hyperglycemia [35]. However, the role of RAGE or accu-
mulation of AGE ligands in the context of TB-DM has
been studied only in animal models but not in people
[31]. Our data reveals that TB-DM and DM individuals
displayed significantly increased circulating levels of AGE
Table 3 Relationship of RAGE ligands with pro-inflammatory
cytokines
RAGE
Ligands
IFNγ TNFα IL-2
r Value p Value r Value p Value r Value p Value
AGE 0.1661 0.1264 0.2403 0.0259 0.33 0.0019
sRAGE 0.2229 0.0369 0.2845 0.0072 0.287 0.0067
S100A12 0.1349 0.2101 0.1123 0.2974 0.135 0.2092
HMGB-1 −0.052 0.6336 0.0308 0.7757 −0.2448 0.0215
Statistical significant values are in bold
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and sRAGE in comparison to TB and HC. In addition, be-
fore, during and after ATT, AGE and sRAGE levels re-
main persistently higher in TB-DM compared to TB. Our
findings also exposed a unique relationship of AGE and
sRAGE levels with the severity of TB disease (as estimated
by the bilateral and cavitary disease) and with measured
bacterial burden. Of further interest was our current re-
sults suggesting that AGE and sRAGE levels correlated
positively with HbA1c, showing a relationship with poorly
uncontrolled glycemia. Since diabetes has a significant im-
pact on the expression of RAGE and its ligands, the role
of RAGE signalling in infection may differ under diabetic
conditions. In general, published data involve RAGE in
the promotion of damaging inflammation, a process that
is well accepted in diabetes, and therefore can also be ra-
tionally incriminated in the comorbidity of diabetes and
infectious disease.
S100A12 is a member of the S100 low molecular weight
family of calcium-binding proteins [36]. Human S100A12 is
largely expressed and discharged by activated neutrophils
[37]. Recent studies highlighted the involvement of S100
proteins with neutrophil related inflammation and their role
as prospective surrogate markers to measure lung inflamma-
tion and disease severity in TB disease [38]. The S100A12 is
the best accepted target protein of RAGE, and in this regard,
S100A12 is known to elicit a pro-inflammatory immune
response by binding to RAGE and activating transcription
factors such as NF-kB [12, 37, 39, 40]. However, moderately
high concentrations of these proteins are essential for RAGE
activation, and they largely are engaged in chronic inflam-
mation [41]. Published studies have reported that elevated
serum levels of S100A12 are correlated with TB disease and
that serum levels of S100A12 are also reported as good
predictors of alveolar lung infiltration as assessed by chest
X-ray [42]. In accordance, the results of our project demon-
strate that TB-DM and DM individuals displayed signifi-
cantly elevated circulating levels of S100A12 in comparison
to TB and HC. In addition, before and during 2nd month
ATT, S100A12 levels remained increased in TB-DM in
comparison to TB. Our current findings also show an asso-
ciation of S100A12 levels with the severity of TB disease (as
estimated by the bilateral and cavitary disease). Our results
also warrant the conclusion that active inflammation in TB-
DM results in increased S100A12 concentrations.
During the time of tissue injury, inflammation and in-
fection, HMGB1, a DNA binding protein will be released
from the nucleus and activates inflammatory and immune
responses through binding to a group of receptors includ-
ing RAGE and members of the TLR family [43, 44]. In
addition, it is also reported that HMGB1 is released by
macrophages, activated monocytes, platelets and neutro-
phils and in turn enables smooth muscle chemotaxis and
proinflammatory responses of endothelial cells [45, 46].
Published studies have described that serum HMGB-1
circulating levels were increased in active TB patients
compared to other lung disease or healthy controls,
whereas in the same study no statistical differences were
seen between the active TB and latent TB patients [47,
48]. In contrast to published studies, our results reveal
that there are significantly diminished levels of HMGB-1
seen in TB-DM and TB in comparison to only DM indi-
viduals but no differences were seen between active TB
disease and HC. In addition, our results also displayed no
significant correlation of HMGB-1 with disease severity,
bacterial burden and glycaemic status, indicating the lack
of association between HMGB-1 with pathogenesis in TB-
DM.
We have previously published that there was a bi-
modal representation of baseline HbA1c between
KDM and NDM individuals in our study cohort, with
significantly increased baseline HbA1c in the KDM
group [16, 49]. In addition, we recently reported that
matrix metalloproteinases (MMPs), which are import-
ant mediators of TB pathology were also significantly
increased in KDM individuals compared to NDM
[50]. Our current findings add to this clear hetero-
geneity in the presentation of TB-DM comorbidity.
The findings from the current project report that sys-
temic RAGE ligands, AGE and sRAGE were signifi-
cantly enhanced in KDM in comparison to NDM
groups, reflecting the enhanced diabetic severity in
KDM individuals. Metformin is an oral antidiabetic
drug that reduces hepatic gluconeogenesis and in-
creases glucose uptake in skeletal muscle through its
effect on the mitochondrial respiratory chain complex
1 and activation of the 5′-adenosine monophosphate-
activated protein kinase (AMPK) [51]. A pioneering
study reported that metformin may hinder the growth
of M.tb and reduce lung inflammation in vivo by an
AMPK-dependent mechanism [52]. Our group also
recently reported that KDM participants on metfor-
min treatment revealed a significantly diminished
levels of MMPs [50]. Our existing results afford fur-
ther evidence of a host-directed therapeutic effect for
metformin based on diminished circulating levels of
AGE and sRAGE.
The expression levels of RAGE, sRAGE, and several
RAGE ligands including S100A12 and HMGB1 are known
to be elevated in DM and to moderately correlate with
poor glycemic control and the development of diabetic
complications [53, 54]. Our findings demonstrate a correl-
ation of plasma sRAGE and RAGE ligands with measures
of TB disease severity, suggesting a possible underlying re-
lationship. One of the limitations of our study is that we
have not controlled for smoking, dietary intake, cardiovas-
cular disease or chronic obstructive pulmonary disease,
which might also affect the markers of inflammation. We
have only measured CML and not the other AGEs.
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Conclusion
We identified that RAGE ligands were significantly en-
hanced in TB-DM and DM in comparison to TB and
HC. We also demonstrated that bacterial burden in TB-
DM was related to elevated circulating levels of RAGE li-
gands. Longitudinal follow-up of RAGE ligands reveal
the alterations of these markers over the course of anti-
TB treatment and provide evidence of unresolved in-
flammation at treatment completion in the TB-DM
group. Our findings also suggest that RAGE ligands can
distinguish KDM from NDM and are modulated by met-
formin therapy.
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